Neuspera
Neuspera Medical is dedicated to developing innovative implantable medical devices aimed at improving the quality of life for patients with chronic illnesses. Their proprietary Mid-Field Powering Technology enables smaller, deeper, and more reliable neuromodulation devices, offering less invasive and more adaptable treatment options. Their initial focus is on a battery-free sacral neuromodulation system for urinary urgency incontinence, with ongoing clinical trials and FDA approval processes. The company's mission is to provide transformative bioelectronic medicine solutions that are less invasive, more effective, and enhance patient well-being.
Industries
Nr. of Employees
small (1-50)
Neuspera
Patents
Products
Battery-free percutaneous sacral neuromodulation system (ultra-miniature implant + external wearable)
An implantable, hermetically sealed, ultra-miniature neurostimulator intended for percutaneous implantation near the sacral nerve, powered by an external wearable transmitter that wirelessly delivers therapy and supports wireless charging; developed to treat urinary urgency incontinence.
Ultra-miniaturized peripheral nerve stimulation system (FDA-cleared)
A leadless micro-implant neuromodulation system cleared by the FDA for peripheral nerve stimulation indications, comprising a micro-implant and wireless wearable transmitter with clinician programming support.
Battery-free percutaneous sacral neuromodulation system (ultra-miniature implant + external wearable)
An implantable, hermetically sealed, ultra-miniature neurostimulator intended for percutaneous implantation near the sacral nerve, powered by an external wearable transmitter that wirelessly delivers therapy and supports wireless charging; developed to treat urinary urgency incontinence.
Ultra-miniaturized peripheral nerve stimulation system (FDA-cleared)
A leadless micro-implant neuromodulation system cleared by the FDA for peripheral nerve stimulation indications, comprising a micro-implant and wireless wearable transmitter with clinician programming support.
Services
Design and management of multi-site pivotal clinical studies, subject enrollment, endpoint tracking, and data generation to support regulatory filings.
Design and management of multi-site pivotal clinical studies, subject enrollment, endpoint tracking, and data generation to support regulatory filings.
Expertise Areas
- Neuromodulation therapy development (sacral and peripheral)
- Wireless power transfer for implantable devices
- Miniaturized implantable device engineering
- Pivotal clinical trial design and execution
Key Technologies
- Mid-field wireless power transfer
- Battery-free percutaneous neurostimulators
- Ultra-miniaturized hermetic implant packaging
- Wearable external transmitters and wireless charging
News & Updates
The company announced the first successful implants of its neuromodulation device in its two-stage pivotal clinical trial for treating urinary urgency incontinence.
Neuspera announced positive six-month results showing the efficacy of its battery-free percutaneous sacral neuromodulation system for UUI, comparable to traditional devices.
The company closed a $23 million Series D funding round led by Vertex Ventures HC and Treo Ventures to support FDA approval and commercialization.
Coverage of Neuspera's progress in clinical trials for its miniaturized neuromodulation systems for UUI and chronic pain.
Details on the company's recent funding round and plans for bringing its innovative devices to market.
Developed the first wireless, battery-free, ultra-miniaturized sacral neuromodulation device for UUI, with positive clinical trial results.
The company announced the first successful implants of its neuromodulation device in its two-stage pivotal clinical trial for treating urinary urgency incontinence.
Neuspera announced positive six-month results showing the efficacy of its battery-free percutaneous sacral neuromodulation system for UUI, comparable to traditional devices.
The company closed a $23 million Series D funding round led by Vertex Ventures HC and Treo Ventures to support FDA approval and commercialization.
Coverage of Neuspera's progress in clinical trials for its miniaturized neuromodulation systems for UUI and chronic pain.
Details on the company's recent funding round and plans for bringing its innovative devices to market.
Developed the first wireless, battery-free, ultra-miniaturized sacral neuromodulation device for UUI, with positive clinical trial results.